ALT

Altimmune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.00
+0.32
+2.74%
After Hours: 11.90 -0.1 -0.83% 19:59 10/23 EDT
OPEN
11.60
PREV CLOSE
11.68
HIGH
12.02
LOW
11.30
VOLUME
540.81K
TURNOVER
--
52 WEEK HIGH
35.10
52 WEEK LOW
1.510
MARKET CAP
394.94M
P/E (TTM)
-5.4365
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Moderna could have Covid-19 test results next month, EUA in December - CEO Bancel
The U.S. could authorize emergency use of Moderna's (MRNA) experimental COVID-19 vaccine in December, according to CEO Stéphane Bancel, if the company gets positive interim results in November from a
Seekingalpha · 3d ago
Moderna not far behind Pfizer on vaccine emergency authorization
The U.S. could authorize emergency use of Moderna's (MRNA) experimental COVID-19 vaccine in December, according to CEO Stéphane Bancel, if the company gets positive interim results in November from a
Seekingalpha · 3d ago
Altimmune to Present at Two Upcoming Virtual Investor Conferences
GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual investor conferences: * H.C. Wainwright Hepatitis B Virus (HBV) Virtual Conference Tuesday, October 20, 2020 – 1:30 pm EDT * B. Riley Securities – Liver Disease Symposium Thursday, October 29, 2020 The H.C. Wainwright HBV presentation will be webcast and can be accessed by visiting the investor relations section of the company's website at www.altimmune.com under Events / Presentations.About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Company’s diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit www.altimmune.com.Investor Contacts:Stacey JurchisonAshley R. Robinson Altimmune, Investor RelationsLifeSci Advisors, LLC Phone: 410-474-8200617-430-7577 sjurchison@altimmune.comarr@lifesciadvisors.com
GlobeNewswire · 10/15 11:00
Mid-Day Market Update: Gold Down 2%; Medigus Shares Spike Higher
Midway through trading Tuesday, the Dow traded down 0.25% to 28,766.88 while the NASDAQ rose 0.19% to 11,899.41. The S&P also fell, falling 0.28% to 3,524.36.
Benzinga · 10/13 16:18
Medigus, Altimmune leads healthcare gainers; Gossamer Bio, Avenue Therapeutics among major losers
Gainers: Medigus (MDGS) +84%, Altimmune (ALT) +25%, Enlivex Therapeutics (ENLV) +16%, BiondVax Pharmaceuticals (BVXV) +16%, Aileron Therapeutics (ALRN) +15%.Losers: Gossamer Bio (GOSS) -34%, Avenue Therapeutics (ATXI) -17%, Emergent BioSolutions (EBS) -13%, AgeX Therapeutics (AGE) -9%, Inozyme Pharma (INZY) -7%.
Seekingalpha · 10/13 15:06
Mid-Morning Market Update: Markets Down; JPMorgan Profit Beats Estimates
Following the market opening Tuesday, the Dow traded down 0.30% to 28749.62 while the NASDAQ fell 0.16% to 11,856.86. The S&P also fell, falling 0.32% to 3,522.84.
Benzinga · 10/13 14:11
The Daily Biotech Pulse: J&J Pauses Coronavirus Vaccine Studies, Voyager's Huntington's Disease Study Placed On Hold, Altimmune Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12)
Benzinga · 10/13 12:20
Altimmunes COVID-19 Vaccine Shows Positive Results; Street Sees 289% Upside
Shares of Altimmune published positive pre-clinical data for its new single-dose, intranasal COVID-19 vaccine candidate AdCOVID. Shares closed 1.9% higher on Monday.The company stated that the study conducted on two strains of mice demonstrated that its AdCOVID elicited multi-faceted immune activity including serum neutralizing immunity, T cell immunity, and mucosal immunity.According to Altimmune (ALT), “AdCOVID is based on the Company’s adenovirus-based intranasal vaccine platform and expresses the receptor binding domain (RBD) of the SARS-CoV-2 spike protein.” The company said, “AdCOVID is designed to offer significant advantages over other COVID-19 vaccine approaches, including intranasal administration, single-dose effectiveness, broad activation of the immune response, and the ability to ship and store the vaccine conveniently and inexpensively.”Altimmune is planning to file an Investigational New Drug (IND) with the US Food and Drug Administration. It expects to initiate a Phase 1 safety and immunogenicity trial of its intranasal COVID-19 vaccine candidate during the fourth quarter. (See ALT stock analysis on TipRanks)Following the AdCOVID update, B. Riley Financial analyst Mayank Mamtani reiterated a Buy rating on the stock with a price target of $31 (146% upside potential). In a note to investors, Mamtani wrote, “We believe ALT remains well positioned to emerge as a leader in the second wave of COVID-19 vaccines, offering a simplistic solution with the potential for self-administration and an attractive stability profile for cold-chain free distribution, conferring the ability to ship and store the vaccine conveniently and inexpensively.”Currently, the Street has a bullish outlook on the stock with a Strong Buy analyst consensus. With shares up over 567% year-to-date, the average price target of $49 implies further upside potential of 288.9% to current levels.Related News: PerkinElmer Raises 3Q Sales Outlook Fueled By COVID-19 Testing Demand J&J Halts Covid-19 Vaccine Trial Due To ‘Unexplained Illness’ Pfizer, BioNTech Initiate Rolling Canada Submission For Covid-19 Vaccine More recent articles from Smarter Analyst: * Dynavax Surges 7% In Pre-Market On Taiwan Covid-19 Vaccine Subsidy * Exelon Jumps On Possible Non-Utility Divestment; Analyst Sees 50% Upside * Nestlé Completes Tender Offer For 84% Stake In Aimmune Therapeutics * New Oriental Rises On Solid Earnings Beat Despite Covid-Headwinds
SmarterAnalyst · 10/13 09:56
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALT. Analyze the recent business situations of Altimmune through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALT stock price target is 49.00 with a high estimate of 80.00 and a low estimate of 31.00.
EPS
Institutional Holdings
Institutions: 70
Institutional Holdings: 13.48M
% Owned: 40.95%
Shares Outstanding: 32.91M
TypeInstitutionsShares
Increased
14
1.10M
New
38
10.66M
Decreased
2
400
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.58%
Pharmaceuticals & Medical Research
+0.69%
Key Executives
Chairman/Director
Mitchel Sayare
President/Chief Executive Officer/Director
Vipin Garg
Chief Financial Officer/Chief Accounting Officer
Will Brown
Chief Financial Officer/Chief Accounting Officer
William Brown
Chief Scientific Officer
M. Scot Roberts
Other
M. Scott Harris
Director
Diane Jorkasky
Independent Director
David Drutz
Independent Director
John Gill
Independent Director
Philip Hodges
Independent Director
Wayne Pisano
Independent Director
Klaus Schafer
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
11/17/2016
Dividend USD 2.91
02/06/2017
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ALT
Altimmune Inc is a clinical-stage immunotherapeutics company. The Company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company’s product candidates include ALT-801, HepTcell, ALT-702, NasoVAX and NasoShield. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, its influenza vaccine candidate that stimulate multiple arms of the immune system and offers the potential to stop the infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is an intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Altimmune Inc stock information, including NASDAQ:ALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALT stock methods without spending real money on the virtual paper trading platform.